What total dose was administered during Phase I Radiation Treatment for Stage III prostate carcinoma?

In the context of Phase I Radiation Treatment for Stage III prostate carcinoma, the total dose typically administered is around 5000 cGy. This dose is part of a fractionated treatment plan that allows for the effective targeting of cancer cells while minimizing damage to surrounding normal tissues.

This dose is established based on clinical practice guidelines and the understanding of tumor responsiveness to radiation. A total dose of 5000 cGy is often used in the curative treatment of prostate cancer, particularly in advanced stages, as it provides a balance between efficacy and tolerability. Higher doses, such as those above 6000 cGy, may be used in subsequent treatment phases, particularly in more aggressive regimes or after reassessment, but the initial phase typically does not exceed 5000 cGy to ensure safety and mitigate acute side effects.

Understanding this dosage framework is crucial for oncology data specialists, as it influences treatment planning, patient management, and data reporting. Proper documentation of treatment doses assists in patient outcomes tracking and research on treatment efficacy.